Autonomix Medical Reports Sustained Quality-of-Life Gains in Pancreatic Cancer Pain Study

Autonomix Medical, Inc. (NASDAQ: AMIX) has announced results from a post-hoc exploratory subgroup analysis of its first-in-human proof-of-concept study (PoC 1) evaluating a targeted ablation therapy for severe pancreatic cancer pain. The study examined the safety and effectiveness of delivering transvascular energy to ablate problematic nerves. The subgroup analysis assessed patient-reported quality-of-life, symptoms, and functional outcomes using the EORTC QLQ-C30 scale across various patient groups, including those with different tumor stages and metastatic status. Results indicated improvements in symptom scores, functionality, and global quality of life at both 4-6 weeks and 3 months post-treatment, with all 3-month results exceeding the EORTC threshold for clinically meaningful change. These findings, along with previously reported pain reduction and opioid-free outcomes, will inform the design of Autonomix’s planned U.S.-based multicenter clinical trial, scheduled to begin in 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here